RUNX2 and neoplasm: 30Kc19α also could improve the stability of the cargo protein, resulting in the treated recombinant protein's prolonged, sustained effect.[28] Therefore, 30Kc19α could deliver RUNX2 with no risk of gene insertional mutagenesis and tumor formation and pass through the hMSC membrane with low cytotoxicity and high efficiency.[5]